	US 12,365,719 B2
	CD80 extracellular domain polypeptides and their use in cancer treatment
Thomas Brennan, Thousand Oaks, CA (US); David Bellovin, Thousand Oaks, CA (US); Barbara Sennino, Thousand Oaks, CA (US); and David Busha, Thousand Oaks, CA (US)
Assigned to Five Prime Therapeutics, Inc., Thousand Oaks, CA (US)
Filed by FIVE PRIME THERAPEUTICS, INC., Thousand Oaks, CA (US)
Filed on May 11, 2022, as Appl. No. 17/742,189.
Application 17/742,189 is a division of application No. 16/295,978, filed on Mar. 7, 2019, abandoned.
Application 16/295,978 is a division of application No. 15/340,238, filed on Nov. 1, 2016, granted, now 10,273,281, issued on Apr. 30, 2019.
Claims priority of provisional application 62/373,654, filed on Aug. 11, 2016.
Claims priority of provisional application 62/249,836, filed on Nov. 2, 2015.
Prior Publication US 2024/0041979 A1, Feb. 8, 2024
Int. Cl. C07K 14/705 (2006.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/70532 (2013.01) [A61K 38/1774 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 35/00 (2018.01); C07K 16/00 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/41 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01)]

18 Claims

1. A method of treating cancer in a subject, which comprises: administering to the subject a composition comprising a CD80 extracellular domain (ECD) fusion protein comprising the amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 21 and a pharmaceutically acceptable carrier.